

## 5 Literaturverzeichnis

Adkins JC et al.: Edrecolomab (monoclonal antibody 17-1A), *Drugs* 1998, 56(4):619-28

Alters SE et al.: Immunotherapy of cancer. Generation of CEA specific CTL peptide pulsed dendritic cells, *Adv Exp Med Biol* 1997; 417:519-24

Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM: phenotypic analysis of antigen-specific T lymphocytes, *Science* 1996, 274(5284):94-6

Amling CL et al.: Diagnosis and management of superficial bladder cancer, *Curr Probl Cancer* 2001; 25(4):219-78

Amici A, Venanzi FM, Concetti A: Genetic immunization against neu/erbB2 transgenic breast cancer, *Cancer Immuno Immunother* 1998; 47:183-190

Amici A., Smorlesi A., Noce G., Santoni G., Cappelletti P., Capparuccia L., Coppari R., Lucciarini R., Petrelli C., Provinciali M.: DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice, *Gene Ther.* 2000; 7(8):703-706

Anichini A, Vegatti C, Mortarini R: The paradox of T cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma, *Cancer Immunol Immunother* 2004; 53(10):855-64. Epub 2004 Jun 03

Arlen P, Tsang KY, Marshall JL, Chen A, Steinberg SM, Poole D, Hand PH, Schlom J, Hamilton JM: The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines, *Cancer Immunol Immunother* 2000; 49(10):517-29

Asemissen AM, Nagorsen D, Keilholz U, Letsch A, Schmittel A, Thiel E, Scheibenbogen C.: Flow cytometric determination of intracellular or secreted IFN $\gamma$  for the quantification of antigen reactive T cells, *J Immunol Methods* 2001; 251(1-2):101-8

Aulitzky W et al.: Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma, *J Clin Oncol* 1989; 7(12):1875-84

Balzar M, Winter MJ, de Boer CJ, Litvinov SV: The biology of the 17-1A antigen (Ep-CAM), *J Mol Med* 1999; 77(10):699-712

Banchereau J, Steinman RM.: Dendritic cells and the control of immunity, *Nature* 1998 Mar 19;392(6673):245-52

Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L: Phase II study of

weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer, *J Clin Oncol* 1996; 14 (3): 737-44  
 Comment in: *J Clin Oncol*. 1996 Mar; 14(3):697-9

Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J.: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts, *Cancer Res* 1998 Jul 1; 58(13):2825-31 Erratum in: *Cancer Res* 1999 Apr 15;59(8):2020

Baselga J et al.: Clinical trial of Herceptin® (trastuzumab), *Eur J Cancer* 2001; 37 Suppl 1:18-24

Baxevanis CN et al.: Tumorspecific cytolysis by TIL in breast cancer, *Cancer* 1994; 74:1275-1282

Bednarek MA, Sauma SY, Gammon MC, Porter G, Tamhankar S, Williamson AR, Zweerink HJ.: The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2, *J Immunol* 1991; 147(12):4047-53

Beechey RT et al.: Adenocarcinoma of the colon: an unusual case, *Med J Aust* 1986; 144(4):211-3

Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR.: Help for cytotoxic-T-cell responses is mediated by CD40 signalling, *Nature* 1998 Jun 4; 393(6684):478-80

Bieganowska K, Hollsberg P, Buckle GJ, Lim DG, Greten TF, Schneck J, Altman JD, Jacobson S, Ledis SL, Hanchard B, Chin J, Morgan O, Roth PA, Hafler DA: Direct analysis of viral-specific CD8+ T cells with soluble HLA-A2/Tax11-19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathy, *J Immunol* 1999, 162(3):1765-71

Blanar MA, Boettger EC, Flavell RA: Transcriptional activation of HLA-DR alpha by interferon gamma requires a trans-acting protein, *Proc Natl Acad Sci USA* 1988, Jul; 85(13):4672-6

Boise LH, Minn AJ, Noel PJ, June CH, Accavitti MA, Lindsten T, Thompson CB.: CD28-Costimulation can promote T cell survival by enhancing the expression of Bcl-XL, *Immunity* 1995 Jul; 3(1):87-98

Bolton PM, Mander AM, Davidson JM, James SL, Newcombe RG, Hughes LE: Cellular immunity in cancer: comparison of delayed hypersensitivity skin tests in three common cancers, *Br Med J* 1975; 3(5974):18-20

Bontkes HJ, de Gruijl TD, van den Muysenberg AF, Verheijen RH, Stukart MJ, Meijer CJ, Scheper RJ, Stacey SN, Duggan-Keen MF, Stern PL, Man S, Borysiewicz LK, Walboomers JM: Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia, *Int J Cancer* 200, 88(1):92-8

Boon T; van der Bruggen P: Human tumor antigens recognized by T lymphocytes, *J Exp Med* 1996; 183:725-729

Boon T; Coulie PG; Van den Eynde B: Tumor antigens recognized by T cells, *Immunology Today* 1997; 18(6):267-268

Boshoff C; Weiss R: AIDS-related malignancies, *Nat Rev Cancer* 2002, 2(5):373-82

Braun S et al.: Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokin-positive tumor cells in bone marrow, *Clin Cancer Res* 1999; 5(12):3999-4004

Bremers AJ et al.: T cell responses in colorectal cancer patients: evidence for class II HLA-restricted recognition of shared tumor-associated antigens, *Int J Cancer* 2000; 88(6):956-961

Brossart P et al.: Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes, *Cancer Res* 1998; 58(4):732-736

Brosterhus H, Brings S, Leyendeckers H, Manz RA, Miltenyi S, Radbruch A, Assenmacher M, Schmitz J: Enrichment and detection of live antigen-specific CD4(+) and CD8(+) T cells based on cytokine secretion, *Eur J Immunol* 1999 Dec; 29(12):4053-9

Burnet FM: Immunological aspects of malignant disease, *Lancet* 1967; 1:1171-1174

Cabrera T et al.: High frequency of altered HLA class I phenotypes in invasive breast carcinomas, *Hum Immunol* 1996; 50(2):127-34

Calhoun RF 2nd, Naziruddin B, Enriquez-Rincon F, Duffy BF, Ritter JM, Sundaresan S, Patterson GA, Cooper JD, Mohanakumar T.: Evidence for cytotoxic T lymphocyte response against human lung cancer: reconstitution of antigenic epitope with peptide eluted from lung adenocarcinoma MHC class I, *Surgery* 2000 Jul; 128(1):76-85

Callan MFC, Tan L, Annels N, Ogg GS, Wilson JDK, O'Callaghan CA, Steven N, McMichael AJ, Rickinson AB: direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr Virus in vivo, *J nExp Med* 1998, 187(9):1395-1402

Cefai D, Morrison BW, Sckell A, Favre L, Balli M, Leunig M, Gimmi CD: Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer; *Int J Cancer* 1999 Oct 29; 83(3):393-400

Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, Nobile M, Appay V, Rizzardi GP, Fleury S, Lipp M, Forster R, Rowland-Jones S, Sekaly RP, McMichael AJ, Pantaleo G: Skewed maturation of memory HIV-specific CD8 T lymphocytes, *Nature* 2001 Mar 1; 410(6824):106-11

Chang AE et al.: Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2, *J Clin Oncol* 1997; 15(2):796-807

Clynes RA et al.: Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets, *Nature Medicine* 2000; 6(4):443-446

Coulie PG et al.: Antitumor immunity at work in a melanoma patient, *Adv Cancer Res* 1999; 76:213-42

Coventry BJ et al.: Lack of IL-2 cytokine expression despite IL-2 messenger RNA transcription in tumor-infiltrating lymphocytes in primary human breast carcinoma: selective expression of early activation markers, *J Immunol* 1996; 156(9):3486-92

Dadmarz R et al.: CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion, *Cancer Immunol Immunother* 1995; 40(1):1-9  
Erratum in: *Cancer Immunol Immunother* 1995; 41(3):201

Dakappagari NK et al.: Prevention of mammary tumours with a chimeric HER-2 B-cell epitope peptide vaccine, *Cancer Res* 2000; 60:3782-3789

Davis MM, Boniface JJ, Reich Z, Lyons D, Hampl J, Arden B, Chien Y.: Ligand recognition by alpha beta T cell receptors, *Annu Rev Immunol* 1998; 16:523-44

de Boer CJ, van Krieken JH, Janssen-van Rhijn CM, Litvinov SV: Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver, *J Pathol* 1999; 188(2):201-6  
Comment in: *J Pathol*. 2000; 191(1):102-3

Derby EG, Reddy V, Nelson EL, Kopp WC, Baseler MW, Dawson JR, Malyguine AM: Correlation of human CD56+ cell cytotoxicity and IFN-gamma production, *Cytokine* 2001; 13(2):85-90

De Smedt T, Pajak B, Muraille E, Lespagnard L, Heinen E, De Baetselier P, Urbain J, Leo O, Moser M: Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo, *J Exp Med*. 1996 Oct 1;184(4):1413-24

De Vries MJ: Treatment of mouse lymphosarcoma by total body irradiation and by injection of bone marrow and lymph node cells, *J Natl Cancer Inst* 1958; 21:117

Di Fabio S, Mbawuike IN, Kiyono H, Fujihashi K, Couch RB, McGhee JR: Quantitation of human influenza virus-specific cytotoxic T lymphocytes: correlation of cytotoxicity and increased numbers of IFN-gamma producing CD8+ T cells, *Int Immunol* 1994; 6(1):11-9

Diel IJ, Cote RJ: Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer, *Cancer Treat Rev* 2000, 26(1):53-65

Ding L, Linsley PS, Germain RN, Shevach EM: IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression, *J Immunol* 1993; 151:1224-34

Disis ML et al.: existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer, *Cancer Res* 1994 Jan; 54:16-20 a)

Disis ML: In vitro generation of human cytolytic T-cells specific for peptides derived from HER-2/neu protooncogene protein, *Cancer Res* 1994 Feb; 54:1071-1076 b)

Disis ML et al.: High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer; *J Clin Oncol* 1997; 15:3363-3367

Disis ML, Grabstein KH, Sleath PR, Chever MA: Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine, *Clin Cancer Res.* 1999 Jun; 5(6):1289-97

Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG: Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer, *Breast Cancer Res and Treat* 2000 a) ; 62:245-252

Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K, Knutson KL : Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization, *Clin Cancer Res.* 2000 b) Apr; 6(4):1347-50

Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn, Cheever MA, Knutson KL, Schiffmann K: Generation of T-cell immunity to the her-2/neu protein after active immunization with her-2/neu peptide-based vaccines, *J Clin Oncol* 2002; 20(11):2624-32

Dobrzanski MJ et al.: Type 1 and type 2 CD8<sup>+</sup> effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor, *J Immunol* 2000; 164(2):916-25

Dobrzanski MJ et al.: Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection, *J Immunol* 2001; 167(1):424-34

Douillard JY et al.: Immunotherapy of gastrointestinal cancer with monoclonal antibodies, *Med Oncol Tumor Pharmacother* 1986; 3(3-4):141-6

Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape, *Nat Immunol* 2002 Nov; 3(11):991-8

Dunnion DJ et al.: Human antigen-presenting cell/tumour cell hybrids stimulate strong allogeneic responses and present tumour-associated antigens to cytotoxic T cells in vitro, *Immunology* 1999; 98(4):541-50

Ehrlich P: Über den jetzigen Stand der Karzinomforschung, *Nederlandsch Tijdschrift voor Geneeskunde* 1909; Erste Heft A No.5:273-290

Ercolini AM, Machiels JP, Chen YC, Slansky JE, Giedlen M, Reilly RT, Jaffee EM: Identification and characterization of the immunodominant rat her-2/neu MHC class I epitope presented by spontaneous mammary tumors from her-2/neu-transgenic mice, *J Immunol* 2003; 170(8):4273-80

Essermann JL et al.: Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice, *Cancer Immunol Immunother* 1999; 47:337-342

Fagerberg J, Steinitz M, Wigzell H, Askelof P, Mellstedt H: Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients, *Proc Natl Acad Sci USA* 1995; 92(11):4773-7

Feurerer M et al.: Enrichment in memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients, *Int J Cancer* 2001 a) :92,96-105

Feurerer M, Beckhove P, Bai L, Solomayer EF, Bastert G, Diel IJ, Pedain C, Oberniedermayr M, Schirmmacher V, Umansky V. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. *Nat Med* 2001 b) ;7(4):452-8

Feurerer M, Beckhove P, Garbi N, Yolanda M, Limmer A, Hommel J, Hämmerling G, Kyewski B, Hamann A, Umansky V, Schirmmacher V: Bone marrow as a priming site for T-cell responses to blood-borne antigen, *Nature Medicine* 2003, 9(9):1151-1157

Fiedler W et al.: A clinical trial of edrecolomab, interleukin-2 and GM-CSF in patients with advanced colorectal cancer, *Oncol Rep* 2001; 8(2):225-31

Finke JH et al.: Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation, *J Immunother Emphasis Tumor Immunol* 1994;15(2):91-104

Fishman P et al.: Autoantibodies to tyrosinase: the bridge between melanoma and vitiligo, *Cancer* 1997; 79(8):1461-4

Fisk B., Blevins T.L., Wharton J.T., Ioannides C.G.: Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines, *J Exp Med* 1995; 181(6):2109-17

Foon KA et al.: Clinical and immune responses in resected colon cancer patients treated with anti-idiotypic monoclonal antibody vaccine that targets the carcinoembryonic antigen, *J Clin Oncol* 1999; 17(9):2889-2885

Gastl G.: Ep-Cam overexpression in breast cancer as a predictor of survival, *The Lancet* 2000; 356

Glauser MP, Zanetti G, Baumgartner JD, Cohen J: Septic shock: pathogenesis, *Lancet* 1991 Sep 21; 338(8769):732-6

Goedegebuure PS et al.: Adoptive immunotherapy with tumor-infiltrating lymphocytes and IL-2 in Pats with metastatic malignant melanoma and renal cell carcinoma: a pilot study, *J Clin Oncol* 1995;13(8):1939-49

Goedegebuure PS, Douville CC, Doherty JM, Linehan DC, Lee KY, Ganguly EK, Eberlein TJ: Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer, *Cell Immunol* 1997; 175(2):150-6

Goldenberg MM et al.: Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer, *Clin Ther* 1999; 21(2):309-18

Goodwin RA, Tuttle SE, Bucci DM, Jewell SD, Martin EW, Steplewski Z: Tumor-associated antigen expression of primary and metastatic colon carcinomas detected by monoclonal antibody 17-1A, *Am J Clin Pathol* 1987; 88(4):462-7

Goto S, Sato M, Kaneko R, Itoh M, Sato S, Takeuchi S: Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients, *Cancer Immunol Immunother* 1999; 48(8):435-42

Graubert TA et al.: How do lymphocytes kill tumor cells?, *Clinical Cancer Research* 1996; 2:785-789

Grosenbach DW, Barrientos JC, Schlom J, Hodge JW: Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects, *Cancer Res* 2001; 61:4497-4505

Guinan EC et al.: Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity, *Blood* 1994; 84(10):3261-82

Gupta SL, Sharma G, Caplen HS, Pyati P, Burnett PM: Involvement of an inducible factor in interferon-gamma-mediated accumulation of HLA gene transcripts, *J Interferon Res*, 1989, Oct; 9(5):531-42

Gure AO, Altorki NK, Stockert E, Scanlan MJ, Old LJ, Chen YT: Human lung cancer antigens recognized by autologous antibodies: definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3, *Cancer Res* 1998 ; 58(5):1034-41

Gure AO, Stockert E, Arden KC, Boyer AD, Viars CS, Scanlan MJ, Old LJ, Chen YT: CT10: a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis, *Int J Cancer* 2000; 85(5):726-32

Guy CT, Cardiff RD, Muller WJ: Activated neu Induces Rapid Tumor Progression *J Biol Chem* 1996; 271(13):7673-8

Hakim AA: Peripheral blood lymphocytes from patients with cancer lack interleukin-2 receptors, *Cancer* 1988, 61:689-701

Haller DG et al.: Update of clinical trials with edrecolomab: a monoclonal antibody therapy for colorectal cancer, *Semin Oncol* 2001; 28(1 Suppl 1):25-30

Hamann et al.: Phenotypic and functional separation of memory and effector human CD8+ T cells, *J Exp Med* 1997; 186(9):1407-18

Hernandez JL et al.: Lymphocyte subpopulations in colo-rectal cancer. Preoperative evaluation, *Allergol Immunopathol (Madr)* 1978; 6(4):339-344

Herr W, Schneider J, Lohse AW, Meyer zum Buschenfelde KH, Wolfel T: Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens, *J Immunol Methods* 1996 May 27; 191(2):131-42

Hom SS et al.: Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction, *J Immunother* 1991; 10(3):153-64

Hom SS et al.: Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared antigens, *J Immunother* 1993 a); 13(1):18-30

Hom SS et al.: Specific immune recognition of autologous tumor by lymphocytes infiltrating colon carcinomas: analysis by cytokine secretion, *Cancer Immunol Immunother* 1993 b); 36:1-8

Horowitz JD, Au FC, Tang CK, Stein B, Campana TJ: Tissue carcinoembryonic antigen levels in benign and malignant diseases of the breast, *J Surg Oncol* 1989 Jan; 40(1):58-60

Hudson JM et al.: Growth and antigen recognition of tumor-infiltrating lymphocytes from human breast cancer, *J Interferon Cytokine Res* 1998; 18(7):529-36

Iezzi G, Karjalainen K, Lanzavecchia A.: The duration of antigenic stimulation determines the fate of naive and effector T cells, *Immunity* 1998 Jan; 8(1):89-95

Ioanides CG et al.: Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene, *Cell Immunol* 1993; 151(1):225-34

Jager E, Stockert E, Zidianakis Z, Chen YT, Karbach J, Jager D, Arand M, Ritter LJ, Knuth A: Humoral immune response of cancer patients against "cancer-testis" antigen NY-ESO-1: correlation with clinical events. *Int. J. Cancer* 1999, 84:506-510

Jass JR, Atkin WS, Cuzick J, Bussey HJR, Morson BC, Northover JMA, Todd IP: The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases, *Histopathology* 1986, 10:437-459



Jerome KR et al.: Cytotoxic t lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells, *Cancer Res* 1991; 51(11):2908-16

Jiang XP et al.: Vaccination with a mixed vaccine of autogenous and allogeneic breast cancer cells and tumor associated antigens CA15-3, CEA and CA125 results in immune and clinical responses in breast cancer patients, *Cancer Biother Radiopharm* 2000; 15(5):495-505

Jojovic M et al.: Epithelial glyxcoprotein-2 expression is subject to regulatory process in epithelial-mesenchymal transitions during metastases: an investigation of human cancers transplanted into severe combined immunodeficient mice, *Histochem J* 1998; 30(10):723-9

Kageshita T et al.: Selective loss of human leukocyte class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of class I human leukocyte antigens, *Cancer Res* 1993; 53(14):3349-54

Kaklamanis L, Townsend A, Doussis-Anagnostopoulou IA, Mortensen N, Harris AL, Gatter KC: Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer, *Am J Pathol* 1994 Sep; 145(3):505-9

Kaklamanis L, Leek R, Koukourakis M, Gatter KC, Harris AL: Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer, *Cancer Res* 1995 Nov 15; 55(22):5191-4

Kapitanovic S et al.: The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer, *Gastroenterology* 1997; 112(4):1103-13

Kappauf H et al.: Complete spontaneous remission in a patient with metastatic non-small-cell lung cancer. Case report, review of the literature, and discussion of possible biological pathways involved, *Ann Oncol* 1997; 8(10):1031-9

Karanikas V et al.: High frequency of cytolytic T lymphocytes directed against a Tumor-specific mutated antigen detectable with HLA tetramers in the blood of lung carcinoma patient with long survival, *Cancer Res* 2001; 61:3718-3724

Kass E et al.: Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with recombinant vaccinia-CEA virus, *Cancer Res* 1999; 59(3):676-683

Katsumata M et al.: Prevention of breast tumour in vivo by downregulation of the p185 neu receptor, *Nature Medecine* 1995; 1(7):644-648

Kawakami Y et al.: Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma, *J Immunother* 2000; 23(1):17-27

Keilholz U et al.: Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients, *J Clin Oncol* 1998; 16(9):2921-9

Khanna R, Burrows SR: role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases, *Annu Rev Microbiol* 2000, 4:19-48

Knutson KL, Schiffman K, Cheever MA, Disis ML: Immunization of cancer patients with her-2/neu, HLA-A2 peptide p369-377, results in short-lived peptide-specific immunity, *Clin Cancer Res* 2002; 8(5):1014-8

Kobayashi H, Wood M, Song Y, Appella E, Celis E.: Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumorantigen, *Cancer Res* 2000 Sep 15; 60(18):5228-36

Kono K et al.: Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes, *Int J Cancer* 1998; 78(2):202-8

Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Muller CA, Becker V, Gross AJ, Hemmerlein B, Kanz L, Muller GA, Ringert RH: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids, *Nat Med* 2000 Mar; 6(3):332-6

Kurts C, Kosaka H, Carbone FR, Miller JF, Heath WR.: Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells, *J Exp Med* 1997 Jul 21; 186(2):239-45

Kvale D, Brandtzaeg P, Lovhaug D: Up-regulation of the expression of secretory component and HLA molecules in a human colonic cell line by tumour necrosis factor-alpha and gamma interferon, *Scand J Immunol*, 1988 Sep; 28(3):351-7

Kvale D, Brandtzaeg P: Constitutive and cytokine induced expression of HLA molecules, secretory component, and intercellular adhesion molecule-1 by butyrate in the colonic epithelial cell line HT-29, *Gut*, 1995, May; 36(5):737-42

Lanzavecchia A; Sallusto F: Dynamics of T lymphocyte Responses: Intermediates, Effectors, and Memory Cells, *Science* 2000; 290:92-97

Lanzavecchia A; Sallusto F: Antigen decoding by T lymphocytes: from synapses to fate determination., *Nat Immunol* 2001 Jun; 2(6):487-92

Lapointe R, Toso JF, Butts C, Young HA, Hwu P: Human dendritic cells require multiple activation signals for the efficient generation of tumor antigen-specific T lymphocytes, *Eur J Immunol* 2000 Nov; 30(11):3291-8

Larsen SU et al.: Spontaneous remission in breast cancer, *Ugeskr Laeger* 1999; 161(26):4001-4

Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM: Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients, *Nat Med* 1999; 5(6):677-85

Legha SS et al.: Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy, *Semin Oncol* 1997; 24;1 Suppl 4:S39-43

Letsch A, Keilholz U, Schadendorf D, Nagorsen D, Schmittel A, Thiel E, Scheibenbogen C: High frequencies of circulating melanoma-reactive CD8+ T Cells in patients with advanced melanoma, *Int J Cancer* 2000; 87,659-664

Levine AM et al.: Lymphoma complicating immunodeficiency disorders, *Ann Oncol* 1994; 5 Suppl 2:29-35

Lienard D et al.: High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and mephalan in isolation perfusion of the limbs for melanoma and sarcoma, *J Clin Oncol* 1992; 10(1):52-60

Linehan DC et al.: Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer, *J Immunol* 1995; 155(9):4486-91

Lise LD, Audibert F: Immunoadjuvants and analogs of immunomodulatory bacterial structures, *Current Opinion in Immunology* 1989; 2:269-274

Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO.: Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule, *J Cell Biol* 1994 Apr; 125(2):437-46

Litvinov SV et al.: Epithelial cell adhesion molecule (Ep-Cam) modulates cell-cell interactions mediated by classic cadherins, *J Cell Biol* 1997, 139(5):1337-48

Luo JS, Kammerer R, Schultze H, von Kleist S: Modulations of the effector function and cytokine production of human lymphocytes by secreted factors derived from colorectal-carcinoma cells, *Int J Cancer* 1997; 72(1):142-8

Mackensen A et al.: Direct evidence to support the immunosurveillance concept in a human regressive melanoma, *J Clin Invest* 1994; 93(4):1397-402

Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L: The origin and function of tumor-associated macrophages, *Immunol Today* 1992; Jul; 13(7):265-70

Maric M, Liu Y: Strong cytotoxic T Lymphocyte responses to a macrophage inflammatory protein 1 $\alpha$ -expressing tumor: Linkage between inflammation and specific immunity, *Cancer Res* 1999; 59:5549-5553

Marincola FM: The multiple ways to tumor tolerance, *Journal of Immunotherapy* 1997; 20(3):178-179

Mathé G et al.: Adoptive Immunotherapy of acute leukemia: experimental and clinical results, *Cancer Res* 1965, Oct; 25(9):1525-31

Matzinger P, Guerder S.: Does T-cell tolerance require a dedicated antigen-presenting cell?, *Nature* 1989 Mar 2; 338(6210):74-6

Maxwell-Armstrong CA: Colorectal Cancer Vaccines, *British Journal of Surgery* 1998; 85(2):149-154

Meehan KR et al.: Ex vivo cytokine activation of peripheral blood stem cells: a potential role for adoptive cellular immunotherapy, *J Hematother Stem Cell Res* 2001; 10(2):283-90

Miconnet I, Coste I, Beermann F, Haeuw JF, Cerottini JC, Bonnefoy JY, Romero P, Renno T: Cancer vaccine design: a novel bacterial adjuvant for peptide-specific CTL induction, *J Immunol* 2001 Apr 1; 166(7):4612-9

Midgley R et al.: Colorectal Cancer, *The Lancet* 1999; 353(9150):391-399

Molina R et al.: c-erbB-2 oncoprotein, CEA and CA 15.3 in patients with breast cancer: prognostic value, *Breast Cancer Res Treat* 1998; 51(2):109-19

Molto L et al.: Immunologic changes in peripheral blood mononuclear cells of patients with metastatic renal cell carcinoma after low doses of subcutaneous immunotherapy with IFN-alpha.2b and IL-2, *J Immunother* 1999; 22(3):260-7

Momburg F et al.: Selective loss of HLA-A or HLA-B antigen expression in colon carcinoma, *J Immunol* 1989; 142(1):352-8

Monsurro V, Nagorsen D, Wang E, Provenzano M, Dudley ME, Rosenber SA, Marincola FM: Functional heterogeneity of vaccine-induced CD8(+) T cells, *J Immunol* 2002 Jun 1; 168(11):5933-42

Morgan DJ, Kreuwel HT, Sherman LA.: Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens, *J Immunol* 1999 Jul 15; 163(2):723-7

Mosmann TR, Li L, Sad D: Functions of CD8 T-cell subsets secreting different cytokine patterns, *Semin Immunol* 1997 a) Apr; 9(2):87-92

Mosmann TR, Li L, Hengartner H, Kagi D, Fu W, Sad S: Differentiation and functions of T cell subsets, *Ciba Found Symp* 1997 b); 204:148-54

Mosolits S et al.: Autoantibodies against the tumour-associated antigen GA733-2 in patients with colorectal carcinoma, *Cancer Immunol Immunother* 1999; 47(6):315-20

Mosolits S, Markovic K, Frodin JE, Virving L, Magnusson CG, Steinitz M, Fagerberg J, Mellstedt H: Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients, *Clin Cancer Res* 2004; 10(16):5391-402

Morin PJ et al.: Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC, *Science* 1997; 275(5307):1787-90; Comment in: *Science* 1997; 275(5307):1752-3

Mortarini R, Piris A, Maurichi A, Molla A, Bersani I, Bono A, Bartoli C, Santinami M, Lombardo C, Ravagnani F, Cascinelli N, Parmiani G, Anichini A: Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma, *Cancer Res* 2003; 63(10):2535-45

Müller P et al.: Übersicht: Entwicklung und Einsatz antiepithelialer Antikörper bei soliden Tumoren, *Der Internist* 2001; 42(6):827-834

Nagorsen D, Keilholz U, Rivoltini L, Schmittel A, Letsch A, Asemissen AM, Berger G, Buhr HJ, Thiel E, Scheibenbogen C: Natural T-cell responses against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu and carcinoembryonic antigen in patients with colorectal cancer, *Cancer Res* 2000; 60(17):4850-4

Nagorsen D, Marincola FM: How to analyse ex vivo T-cell responses in cancer patients, *In Vivo* 2002 a); 16(6):519-25

Nagorsen D, Marincola FM, Kaiser HE: Bacteria-related spontaneous and therapeutic remission of human malignancies, *In Vivo* 2002 b), 16:551-556

Nagorsen D, Scheibenbogen C, Schaller G, Leigh B, Schmittel A, Letsch A, Thiel E, Keilholz U: Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients, *Int J Cancer*. 2003 Jun 10; 105(2):221-5.

Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H: CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer, *Cancer Res* 1998; 58(16):3491-4

Natali PG et al.: Selective changes in expression of HLA class I polymorphic determinants in human solid tumors, *Proc Natl Acad Sci USA* 1989; 86(17):6719-23

Natali PG et al.: Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues, *Int J Cancer* 1990; 45(3):457-61

Okamoto M et al.: Enhancement of anti-cancer immunity by a lipoteichoic-acid-related molecule isolated from a penicillin-killed group A Streptococcus, *Cancer Immunol Immunother* 2001; 50(8):408-16

Old LJ; Chen YT: New Paths in Human Cancer Serology, *J Exp Med* 1998; 187(8):1163-1167

Old LJ: Cancer/Testis (CT) antigens - a new link between gametogenesis and cancer, *Cancer Immunity* 2001, Vol. 1, p. 1

Packeisen J, Kaup-Franzen C, Knieriem HJ: Detection of surface antigen 17-1A in breast and colorectal cancer, *Hybridoma* 1999 Feb; 18(1):37-40

Pavone L et al.: Long-term treatment with low doses of interleukin-2 and interferon-alpha: immunological effects in advanced renal cell cancer, *Cancer Immunol Immunother* 2001; 50(2):82-6

Pegram MD et al.: Combination of therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity, *Semin Oncol* 1999; 26(4 Suppl 12):89-95

Peiper M et al.: The HER-2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes, *Eur J Immunol* 1997; 27(5):1115-23

Peoples GE, Schoof DD, Andrews JV, Goedegebuure PS, Eberlein TJ: T-cell recognition of ovarian cancer, *Surgery* 1993 a) Aug; 114(2):227-34

Peoples GE, Goedegebuure PS, Andrews JV, Schoof DD, Eberlein TJ: HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer, *J Immunol* 1993 b) Nov 15; 151(10):5481-91

Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ: Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER-2/neu-derived peptide, *Proc Natl Acad Sci USA* 1995 a); 92(2):432-6

Peoples GE, Smith RC, Linehan DC, Yoshino I, Goedegebuure PS, Eberlein TJ: Shared T cell epitopes in epithelial tumors, *Cell Immunol* 1995 b); 164(2):279-86

Perdigon G, Fuller R, Raul R: Lactic acid bacteria and their effect on the immune system, *Curr. Issues Intest. Microbiol.* 2001; 2(1):27-42

Piccard M et al.: Closing remarks and treatment guidelines, *Eur J Cancer* 2001; 37 Suppl 1:30-33

Pittet MJ, Valmori D, Dunbar PR, Speiser DE, Liénard D, Lejeune F, Fleischhauer K, Cerundolo V, Cerottini J-C, Romero P: High frequencies of naïve Meelan-A/MART-1-specific CD8+ T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals, *J. Exp. Med.* 1999; 190(5):705-715

Plautz GE et al.: T-cell adoptive immunotherapy of metastatic renal cell carcinoma, *Urology* 1999; 54(4):617-24

Prescott S et al.: Mechanisms of action of intravesical bacille Calmett-Guerin: local immune mechanisms, *Clin Infect Dis* 2000; 31 Suppl 3:S91-3

Punt CJ, Nagy A, Douillard JY, Figer A, Skovsgaard T, Monson J, Barone C, Fountzilas G, Riess H, Moylan E, Jones D, Dethling J, Colman J, Coward L, MacGregor S.: Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study, *Lancet* 2002 Aug 31; 360(9334):671-7

Pupa SM, Menard S, Andreola S, Colnaghi MI: Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients, *Cancer Res* 1993 Dec 15; 53(24):5864-6

Ras E et al.: Identification of Potential HLA-A \*0201 Restricted CTL Epitopes Derived from the Epithelial Cell Adhesions Molecule (Ep-CAM) and the Carcinoembryonic Antigen (CEA), *Human Immunology* 1997; 53(1):81-89

Reilly RT et al.: HER-2/*neu* is a tumor rejection target in tolerized HER-2/*neu* transgenic mice, *Cancer Res* 2000; 60:3569-3576

Reilly RT et al.: The collaboration of both humoral and cellular HER-2/*neu*-targeted immune responses is required for the complete eradication of HER-2/*neu*-expressing tumors, *Cancer Res* 2001; 61(3):880-3

Renkvist N, Castelli C, Robbins PF, Parmiani G: A listing of human tumor antigens recognized by T cells, *Cancer Immunol Immunother* 2001; 50:3-15

Rentzsch C, Kayser S, Stumm S, Watermann I, Walter S, Stevanovic S, Wallwiener D, Gückel B: Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells, *Clin Cancer Res* 2003, 9:4376-4386

Riethmuller G, Schneider-Gadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, et al.: Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group, *Lancet* 1994 May 14; 343(8907):1177-83

Riethmuller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Funke I, Pichlmaier H, Hirche H, Buggisch P, Witte J, Pichlmayr R: Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial, *J Clin Oncol* 1998; 16(5):1788-94

Rimm DL et al.: Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma, *Am J Pathol* 1999; 154(2):325-9

Rodolfo M, Luksch R, Stockert E, Chen YT, Collini P, Ranzani T, Lobardo C, Dalerba P, Rivotlini L, Arienti F, Fossati-Bellani F, Old LJ, Parmiani G, Castelli C: Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen, *Cancer Res* 2003, 63(20):6948-55

Rongcun Y et al.: Identification of new HER-2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas, *J Immunol* 1999; 163(2):1037-44

Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Vetto JT, Seipp CA, Simpson C: A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2, *Surgery* 1986 Aug; 100(2):262-72

Rosenberg SA et al.: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report, *N Engl J Med* 1988; 319(25):1676-80

Rosenberg SA: Progress in human tumour immunology and immunotherapy, *Nature* 2001; 411:380-384

Ross JS, McKenna BJ: The HER-2/neu oncogene in tumors of the gastrointestinal tract, *Cancer Invest* 2001; 19(5):554-68

Rubinfeld B et al.: Stabilization of beta-catenin by genetic defects in melanoma cell lines, *Science* 1997; 275(5307):1790-2

Rudolf MP, Man S, Melief CJ, Sette A, Kast WM: human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7, *Clin Cancer Res* 2001, 7(3Suppl):788s-795s

Rye PD et al.: MUC1: antibodies and immunoassays, *Tumour Biol* 2001; 22(4):269-72

Sad D, Li L, Mosmann TR: Cytokine-deficient CD8+ Tc1 cells induced by IL-4: retained inflammation and perforin and Fas cytotoxicity but compromised long term killing of tumor cells, *J Immunol* 1997 Jul 15; 159(2):606-13

Saint F et al.: Mechanisms of action of BCG: towards a new individualized therapeutic approach?, *Prog Urol* 2000; 10(6):1118-26

Sallusto F; Lanzavecchia A: Mobilizing dendritic cells for tolerance, priming, and chronic inflammation, *J Exp Med.* 1999; 189(4):611-4

Sallusto F; Lanzavecchia A: Exploring pathways for memory T cell generation, *J Clin Invest* 2001; 108:805-806



Scanlan MJ, Chen YT, Williamson B, Gure AO, Stockert E, Gordan JD, Tureci O, Sahin U, Pfreundschuh M, Old LJ: Characterization of human colon cancer antigens recognized by autologous antibodies, *Int J Cancer* 1998; 76(5):652-8

Scheibenbogen C, Lee KH, Mayer S, Stevanovic S, Moebius U, Herr W, Rammensee HG, Keilholz U: A sensitive ELISPOT assay for detection of CD8<sup>+</sup> T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients, *Clin Cancer Res* 1997 a); 3(2):221-6

Scheibenbogen C, Lee KH, Stevanovic S, Witzens M, Willhauck M, Waldmann V, Naehrer H, Rammensee HG, Keilholz U: Analysis of the T cell response to tumor and viral peptide antigens by an IFN $\gamma$ -ELISPOT assay, *Int J Cancer* 1997 b); 71(6):932-6

Scheibenbogen C, Romero P, Rivoltini L, Herr W, Schmittel A, Cerottini JC, Woelfel T, Eggermont AM, Keilholz U: Quantitation of antigen-reactive T cells in peripheral blood by IFN $\gamma$ -ELISPOT assay and chromium-release assay: a four-centre comparative trial, *J Immunol Methods* 2000; 244(1-2):81-9

Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S, Nagorsen D, Keilholz U: CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia, *Blood* 2002 Sep 15; 100(6):2132-7

Scheibenbogen C, Letsch A, Schmittel A, Asemisen AM, Thiel E, Keilholz U: Rational peptide-based tumour vaccine development and T cell monitoring, *Semin Cancer Biol.* 2003, Dec;13(6):423-9

Schiltz PM, Beutel LD, Nayak SK, Dillman RO: Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer, *J Immunother* 1997; 20(5):377-86

Schmielau J et al.: Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients, *Cancer Res* 2001 Jun 15; 61(12):4756-60

Schmittel A, Keilholz U, Scheibenbogen C: Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood, *J Immunol Methods* 1997; 210(2):167-74

Schmittel A, Keilholz U, Thiel E, Scheibenbogen C: Quantification of tumor-specific T lymphocytes with the ELISPOT assay, *J Immunother* 2000; 23(3):289-95

Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ: T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions, *Nature* 1998 Jun 4; 393(6684):480-3

Schrum AG, Wells AD, Turka LA: Enhanced surface TCR replenishment mediated by CD28 leads to greater TCR engagement during primary stimulation, *Int Immunol* 2000 Jun; 12(6):833-42

Schwartz RH: Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy, *Cell* 1992 Dec 24; 71(7):1065-8

Schwartzberg LS et al.: Clinical experience with edrecolomab: monoclonal antibody therapy for colorectal carcinoma, *Crit Rev Oncol Hematol* 2001; 40(1):17-24

Schwartzentruber DJ et al.: Charakterization of lymphocytes infiltrating breast cancer: specific immune reactivity detected by measuring cytokine release, *J Immunother* 1992; 12:1-12

Shirai H et al.: Expression of growth factors and their receptors in human early colorectal carcinomas: immunohistochemical study, *Anticancer Res* 1995; 15(6B):2889-94

Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, *Science* 1989 May 12; 244(4905):707-12

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, *N Engl J Med* 2001; 344(11):783-92

Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA.: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin), *Semin Oncol* 1999; 26(4 Suppl 12):60-70

Smyth MJ, Godfrey DI, Trapani JA: A fresh look at tumor immunosurveillance and immunotherapy, *Nature Immunology* 2001 a); 2(4):293-299

Smyth MJ, Trapani JA: Lymphocyte-mediated immunosurveillance of epithelial cancers? *Trends Immunol* 2001 b) Aug; 22(8):409-11

Sosemann JA et al.: Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion, *J Clin Oncol* 2001; 19(3):634-44

Staib L et al.: Immunogenicity of recombinant GA733-2E antigen (CO17-1A; KS1-4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients, *Int J Cancer* 2001; 92(1):79-87

Starzl TE et al.: Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy, *Lancet* 1984; 1(8377):583-7

Staveley-O'Carroll K et al.: Induction of antigen-specific T cell anergy: an early event in the course of tumor progression, *Proc Natl Sci USA* 1998; 95(3):1178-83

Steele RJC, Eremin O, Brown M, Hawkins RA: A high macrophage content in human breast cancer is not associated with favourable prognostic factors, *Br. J Surg*, 1984, 71:456-458

Steinman RM, Inaba K, Turley S, Pierre P, Mellman I: Antigen capture, processing, and presentation by dendritic cells: recent cell biological studies, *Hum Immunol* 1999 a) Jul; 60(7):562-7

Steinman RM, Inaba K.: Myeloid dendritic cells, *J Leukoc Biol* 1999 b) Aug; 66(2):205-8

Stephan JP, Roberts PE, Bald L, Lee J, Gu Q, Devaux B, Mather JP: Selective cloning of cell surface proteins involved in organ development: epithelial glycoprotein is involved in normal epithelial differentiation, *Endocrinology* 1999 Dec; 140(12):5841-54

Stuehr DJ, Nathan CF: Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells, *J Exp Med* 1989; 169(5):1543-55

Suni MA, Picker LJ, Maino VC: Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry, *J Immunol Methods* 1998; 212(1):89-98

Tanaka F et al.: Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells, *Cancer Res* 2000; 60(17):4838-44

Tandon AK, Clark GM, Chamness GC, McGuire WL: Association of the 323/A3 surface glycoprotein with tumor characteristics and behavior in human breast cancer, *Cancer Res* 1990 Jun 1; 50(11):3317-21

Titu LV, Monson JRT, Greenman J: The role of CD8+ T cells in immune responses to colorectal cancer, *Cancer Immunol Immunother* 2002; 51: 235-247

Tokunaga T, Yamamoto H, Shimada S, Abe H, Fukuda T, Fujisawa Y, Furutani Y, Yano O, Kataoka T, Sudo T et al.: Antitumor activity of deoxyribonucleic acid fraction from *Mycobacterium bovis* BCG. I. Isolation, physicochemical characterization, and antitumor activity, *J Natl Cancer Inst* 1984; 72(4):955-62

Toomey D, Harmey J, Condrón C, Kay E, Bouchier-Hayes D: Phenotyping of immune cell infiltrates in breast and colorectal tumours, *Immunol Invest* 1999 Jan; 28(1):29-41

Trojan A et al.: Generation of cytotoxic T Lymphocytes against native and altered peptides of human leukocyte antigen-A 0201 restricted epitopes from the human epithelial cell adhesion molecule, *Cancer Res* 2001; 61:4761-4765

Tsang KY et al.: Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine, *J Natl Cancer Inst* 1995; 87(13):982-990

Tsang KY, Zhu M, Nieroda CA, Correale P, Zaremba S, Hamilton JM, Cole D, Lam C, Schlom J: Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen, *Clinical Cancer Research* 1997; 3(12):2439-2449

Turley SJ, Inaba K, Garrett WS, Ebersold M, Unternaehrer J, Steinman RM, Mellman I: Transport of peptide-MHC class II complexes in developing dendritic cells, *Science* 2000 Apr 21; 288(5465):522-7

Turley SJ: Dendritic cells: inciting and inhibiting autoimmunity, *Curr. Op. in Immunol* 2002, 14:765-770

Tzankov A et al.: Spontaneous remission in a secondary acute myelogenous leukaemia following invasive pulmonary aspergillosis, *Ann Hematol* 2001; 80(7):423-5

Valmori D, Scheibenbogen C, Dutoit V, Nagorsen D, Asemissen AM, Rubio-Godoy V, Rimoldi D, Guillaume P, Romero P, Schadendorf D, Lipp M, Dietrich PY, Thiel E, Cerottini JC, Lienard D, Keilholz U: Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity, *Cancer Res* 2002 a) Mar 15; 62(6):1743-50

Valmori D, Dutoit V, Schnuriger V, Quiquerez AL, Pittet MJ, Guillaume P, Rubio-Godoy V, Walker PR, Rimoldi D, Lienard D, Cerottini JC, Romero P, Dietrich PY: Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity, *J Immunol* 2002 b) Apr 15; 168(8):4231-40

Van den Eynde; Boon 1997: Tumor antigens recognized by T lymphocytes, *International Journal of Clinical + Laboratory Research* 1997; 27(2):81-86

van der Bruggen P et al.: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma, *Science* 1991; 254(5038):1643-7

van der Meijden AP, Brausi M, Zambon V, Kirkels W, de Balincourt C, Sylvester R: Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial, *J Urol* 2001 Aug; 166(2):476-81

Verdegaal ME et al.: Isolation of broadly reactive tumor-specific, HLA class-I restricted CTL from blood lymphocytes of breast cancer patient, *Human Immunology* 1999; 60:1195-1206

Vermorken JB et al.: Active specific immunotherapy for stage II and stage III human colon cancer: a randomized trial, *Lancet* 1999; 353(9150):345-50

Wang RF: Human tumor antigens: implications for cancer vaccine development, *Journal of Molecular Medicine* 1999 a); 77(9):640-655

Wang RF; Rosenberg SA: Human tumor antigens for cancer vaccine development, *Immunologic reviews* 1999 b); 170:85-100

Ward RL, Hawkins NJ, Coomber D, Disis ML: Antibody immunity to HER-2/neu oncogenic protein in patients with colorectal cancer, *Human Immunology* 1999; 60(6):510-515

Wiemann B, Starnes CO: Coley's toxins, tumor necrosis factor and cancer research: a historical perspective, *Pharmacol Ther* 1994; 64(3):529-64

Wilkinson J, Cope A, Gill J, Bourboulia D, Hayes P, Imami N, Kubo T, Marcelin A, Calvez V, Weiss R, Gazzard B, Boshoff C, Gotch F: identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy, *J Virol* 2002, 76(6):2634-40

Xiang R et al.: Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral vaccine in CEA-transgenic mice, *Clin Cancer Res* 2001; 7(3 Suppl):856s-864s

Ye X, McCarrick J, Jewett L, Knowles BB: Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice, *Proc Natl Acad Sci USA* 1994; 91(9):3916-3920

Yoo YK, Heo DS, Hata K, Van Thiel DH, Whiteside TL: Tumor-infiltrating lymphocytes from human colon carcinomas. Functional and phenotypic characteristics after long-term culture in recombinant interleukin 2, *Gastroenterology* 1990; 98(2):259-268

Yoshino I, Peoples GE, Goedegebuure PS, Maziarz R, Eberlein TJ: Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer, *J Immunol* 1994 a); 152(5):2393-400

Yoshino I, Goedegebuure PS, Peoples GE, Parikh AS, DiMaio JM, Lyerly HK, Gazdar AF, Eberlein TJ: HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer, *Cancer Res* 1994 b); 54(13):3387-90

Youde SJ, Dunbar PR, Evans EM, Fiander AN, Borysiewicz LK, Cerundolo V, Man S, Use of fluorogenic histocompatibility leukocyte antigen-A\*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens, *Cancer Res* 2000, 60(2):365-71

Zea AH et al.: Alterations in T cell receptor signaling transduction molecules in melanoma patients, *Clin Cancer Res* 1995; 1(1):1327-35

Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer, *N Engl J Med.* 2003 Jan 16; 348(3):203-13

Zhong XY et al.: Evaluatin GA733-2 mRNA as a marker for the detection of micrometastatic breast cancer in peripheral blood and bone marrow, Arch Gynecol Obstet 1999; 263;(1-2):2-6